John P Brancaccio
CIK 1276551 · Chairman · last filed 2026-08-07
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
CRDF price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
11 DEER PARK DRIVE, SUITE 204
MONMOUTH JUNCTION, NJ 08852
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| OKYO | Director | 35,201 | $1.46 | $51.2K | $39.8K | 5 | 2026-08-07 |
| Hepion Pharmaceuticals, Inc. (HEPA) Delisted | Chairman | 7 | $0.08 | $1 | $10.7K | 6 | 2024-02-21 |
| CRDF | Director | 12,260 | $0.80 | $9.9K | $42.8K | 6 | 2022-06-09 |
| Cardiff Oncology, Inc. (TROV) Delisted | Director | 13,598 | — | — | $16.0K | 7 | 2019-06-24 |
| SYNERGY PHARMACEUTICALS, INC. (SGYP) Delisted | Director | 116,571 | — | — | $23.3K | 5 | 2018-07-06 |
| Hepion Pharmaceuticals, Inc. (CTRV) Delisted | Director | — | — | — | $0 | 2 | 2018-07-03 |
| Cardiff Oncology, Inc. (TROVW) Delisted | Director | — | — | — | $0 | 7 | 2017-01-05 |
| SYNERGY PHARMACEUTICALS, INC. (SGYPW) Delisted | Director | 21,883 | — | — | -$14.5K | 11 | 2016-09-21 |
| ACEL | Director | 6,300 | $11.15 | $70.2K | $4.5K | 5 | 2009-01-05 |
| CALLISTO PHARMACEUTICALS INC (KAL) Delisted | Director | — | $1.12 | — | $0 | 1 | 2007-09-28 |
Recent Filings · Page 5 of 7
69 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2014-12-09 | SYNERGY PHARMACEUTICALS, INC. (SGYPW) Delisted | Grant (A) | — | $0 | EDGAR |
| 2014-12-04 | — | Grant (A) | — | $0 | |
| 2014-03-14 | — | Grant (A) | — | $0 | |
| 2014-03-07 | — | Buy (P) | +4,393 | $6.5K | |
| 2014-02-26 | Cardiff Oncology, Inc. (TROVW) Delisted | Grant (A) | — | $0 | EDGAR |
| 2014-02-20 | — | Other (J) | +2,015 | $0 | |
| 2014-01-28 | — | Grant (A) | — | $0 | |
| 2013-07-17 | SYNERGY PHARMACEUTICALS, INC. (SGYPW) Delisted | Grant (A) | — | $0 | EDGAR |
| 2013-07-16 | SYNERGY PHARMACEUTICALS, INC. (SGYPW) Delisted | Grant (A) | — | $0 | EDGAR |
| 2013-02-21 | Cardiff Oncology, Inc. (TROVW) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.